CGM
VRTX icon

Capital Growth Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Capital Growth Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-37,000
Closed -$10.7M – 68
2020
Q2 		$10.7M Sell
37,000
-48,000
-56% -$13M 1.25% 34
2020
Q1 		$20.2M Buy
+85,000
New +$19.5M 2.84% 15

Other funds holding VRTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Capital Growth Management's VRTX Position: Q3 2020 in Review

Capital Growth Management sold out of Vertex Pharmaceuticals (VRTX) in Q3 2020, closing a stake of 37,000 shares — an estimated $10.7M sold.

Capital Growth Management first reported a position in VRTX in Q1 2020 and held it in 2 quarters. The position peaked at $20.2M in Q1 2020. 950 funds tracked by Wall St. Rank hold VRTX as of Q3 2020.

  • Capital Growth Management reported no remaining Vertex Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • Capital Growth Management sold 37,000 Vertex Pharmaceuticals shares in Q3 2020, an estimated $10.7M.
  • Capital Growth Management first reported a position in Vertex Pharmaceuticals in Q1 2020 and held it in 2 quarters.
  • Capital Growth Management's Vertex Pharmaceuticals position peaked at $20.2M in Q1 2020.
  • 950 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2020.

Based on Capital Growth Management's 13F filing for Q3 2020, filed 12 Nov 2020.